Company Statements 2024

Biocon Biologics  /  Company Statements  /  Company Statements 2024

Japan Health Authority (PMDA) Approves Biocon Biologics’ Ustekinumab BS, Biosimilar to J&J’s Stelara®

  • Posted by: Biocon Biologics

EMA’s CHMP recommends approval of Biocon Biologics’ YESINTEK®, biosimilar to J&J’s Stelara®

  • Posted by: Biocon Biologics

U.S. FDA Approves Biocon Biologics’ YESINTEK™, Bmab 1200 biosimilar to J&J’s Stelara® (Ustekinumab)

  • Posted by: Biocon Biologics

USFDA Classifies Biocon Biologics’ Biocon Park Site in Bengaluru, India as Voluntary Action Initiated (VAI)

  • Posted by: Biocon Biologics

Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)

  • Posted by: Biocon Biologics

US FDA Completes Inspection at Biocon Biologics’ Insulins Facility at Johor Bahru, Malaysia

  • Posted by: Biocon Biologics

US FDA Completes Inspection at Biocon Biologics’ Facilities at Biocon Park, Bengaluru, India

  • Posted by: Biocon Biologics

EMA Approves Biocon Biologics’ New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites

  • Posted by: Biocon Biologics

Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®

  • Posted by: Biocon Biologics

Company Statement on rh-Insulin for Veterinary use

  • Posted by: Biocon Biologics
  • 1
  • 2
Share
buy twitter followers - omegle - matadorbet güncel adres - onwin - onwin güncel adres